uniQure's AMT-130 Gene Therapy for Huntington's Disease on Track for Q1 2026 BLA Submission After FDA Alignment
uniQure (NASDAQ:QURE) is one of the biotech stocks to buy according to Wall Street analysts.
Uniqure N.v. (QURE)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Vestal Point Capital Ryan Wilder | 4,792,572 | $50,801,263 | +59% | 3.63% |
| 2. | EcoR1 Capital Oleg Nodelman | 3,988,971 | $42,283,093 | +18% | 2.51% |
| 3. | Nantahala Capital Management Wilmot B. Harkey And Daniel Mack | 2,755,962 | $29,213,197 | +13% | 1.16% |
| 4. | VenBio Select Advisor Kurt Von Emster | 2,175,000 | $23,055,000 | 0.36% | |
| 5. | 683 Capital Partners Ari Zweiman | 1,550,000 | $16,430,000 | +2% | 1.13% |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $13.92 | 1,466 | $20,406.72 | 150,437 | 2025-06-27 | Filing | |
| $14.45 | 2,112 | $30,518.40 | 37,694 | 2025-06-20 | Filing | |
| $14.45 | 2,112 | $30,518.40 | 29,937 | 2025-06-20 | Filing | |
| $14.45 | 2,112 | $30,518.40 | 20,439 | 2025-06-20 | Filing | |
| $14.45 | 2,112 | $30,518.40 | 28,346 | 2025-06-20 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 2,750,714 | $38,344,953 | 0.07% | |
| 2. | 603,210 | $8,411,066 | 0% | |
| 3. | 447,486 | $6,260,329 | 1.35% | |
| 4. | 348,328 | $4,855,697 | 0% | |
| 5. | 140,060 | $1,952,436 | 0% |
News See All
10 Biotech Stocks to Buy According to Wall Street Analysts
On July 8, Jared Holz, Mizuho, joined 'Closing Bell Overtime' on CNBC to discuss if the biotech sector is ready for a breakout.
uniQure N.V. (NASDAQ:QURE) Q2 2025 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the uniQure Second Quarter 2025 Earnings Conference Call.
Lake Street: AMT-130 Could Be Game-Changer For ClearPoint
uniQure N.V. (NASDAQ:QURE) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds.
11 Best Genomics Stocks to Buy According to Hedge Funds
Genomics is the study of genes and how they operate.
uniQure N.V. (NASDAQ:QURE) Q1 2025 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to the uniQure First Quarter 2025 Earnings Conference Call. At this time all participants are in a listen-only mode.
12 Most Promising Growth Stocks According to Wall Street Analysts
The new regulatory environment has the technology sector eyeing prominent growth opportunities in 2025 and beyond.
Why These 24 Stocks Are Skyrocketing
One of the strongest stock market anomalies is the momentum effect, which is the tendency of recent past winners to outperform the recent past losers.
12 Best Growth Stocks to Buy and Hold in 2025
The latest data from the job market in the United States came out on Friday and that has made the future of rate cuts even more uncertain.
13 Best Biotech Stocks To Buy Under $20
In this article, we're going to take a look at 13 best biotech stocks to buy under $20.
Billionaire Hedge Funds
